# Safety of Ticagrelor+ Warfarin in Comparison With Clopidogrel+Aspirin+Warfarin

Study · id `cardio:ct-nct02206815` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02206815](<https://clinicaltrials.gov/study/NCT02206815>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02206815

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 296 participants.

## Technical summary

Registry record NCT02206815. Randomized; no masking; primary purpose treatment. Start 2014-09-19 (actual); primary completion 2019-02-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 296 participants (enrolled count; ClinicalTrials.gov record NCT02206815, source copy `cardio:ctgov-nct02206815-2023-04-14`, retrieved 2026-10-26)
- Started: 2014-09-19 (actual) (ClinicalTrials.gov record NCT02206815, source copy `cardio:ctgov-nct02206815-2023-04-14`, retrieved 2026-10-26)
- Primary completion: 2019-02-20 (actual) (ClinicalTrials.gov record NCT02206815, source copy `cardio:ctgov-nct02206815-2023-04-14`, retrieved 2026-10-26)
- Completion: 2019-02-20 (actual) (ClinicalTrials.gov record NCT02206815, source copy `cardio:ctgov-nct02206815-2023-04-14`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02206815, source copy `cardio:ctgov-nct02206815-2023-04-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02206815-2023-04-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"
- Condition: Atrial Fibrillation
- Condition: Coronary Artery Disease
- Intervention (Drug): Ticagrelor+Warfarin
- Intervention (Drug): Clopidogrel+Aspirin+Warfarin
- Lead sponsor: Genshan Ma
- Lead sponsor class: OTHER
- Collaborator: Zhongda Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: Zhongda Hospital (`cardio:org-zhongda-hospital`)

## Provenance

Content hash: f9c580782793539518207d32bfb1fc8fe41785d818b883128c4b821fab4f632d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
